Abstract
Background/Objectives: Metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of metabolic dysfunction-associated steatotic liver disease (MASLD), significantly impairs patient well-being and productivity and imposes immense clinical and economic burdens worldwide. Lifestyle modifications, such as increased physical activity and healthy diets, have been the cornerstone of MASLD/MASH management. The recent conditional approval of Wegovy and Rezdiffra for patients with MASH represents a milestone in disease management. However, the lack of response to these medications in some patients, as well as some adverse drug reactions, underscores the need to identify additional strategies to curb MASH progression. Our study aimed to investigate the potential contribution of Manuka honey to the MASH management regimen. Methods: Male C57BL/6J mice were fed a choline-deficient, 0.1% methionine-added high-fat diet (CDAHFD) for 12 weeks to induce MASH. Concurrently, mice were orally administered 8 g/kg of Manuka honey in phosphate-buffered saline (PBS) or PBS alone every week (n = 7–8/group). Liver tissues and plasma were collected upon euthanasia for further histopathological and molecular characterization. Results: Weekly oral administration of Manuka honey alleviated hepatic injury, inflammation, and fibrosis in CDAHFD-induced MASH mice but did not affect steatosis. At the molecular level, Manuka honey upregulated genes governing oxidative phosphorylation and fatty acid oxidation but downregulated those involved in inflammatory responses, monocyte infiltration, and fibrosis. These transcriptional changes correlated with increased hepatic ATP production and reduced expression of pro-inflammatory and pro-fibrotic proteins. Conclusions: Our study demonstrates the hepatoprotective effects of Manuka honey against cellular injury, inflammation, and fibrosis in diet-induced MASH mice. Honey, a natural food used since ancient times, may offer a patient-friendly complementary approach to MASH management.